Here are relevant reports on : proton-therapy-market
-
Viral Vector & Plasmid DNA Manufacturing Market by Type (Viral Vector (Retroviruses, Adenoviruses, AAV, Lentiviruses), Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User - Global Forecast to 2028
The global viral vector manufacturing market, valued at US$4.8 billion in 2022, stood at US$5.5 billion in 2023 and is projected to advance at a resilient CAGR of 18.2% from 2023 to 2028, culminating in a forecasted valuation of US$12.8 billion by the end of the period. The growth of this market is majorly driven by g rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, and effectiveness of viral vectors in gene therapy delivery.
- Published: June 2023
- Price: $ 4950
- TOC Available:
-
Hemophilia Treatment Market by Indication (Type A, Type B), Therapy (Replacement (Recombinant, Plasma Derived), Route of Administration, End User - Global Forecast to 2027
The global hemophilia treatment market is projected to reach USD ~15 billion by 2027 from USD 12 Billion in 2022, at a CAGR of 5% during the forecast period. The major players in the global hemophilia market are Bayer Healthcare (Germany), Octapharma AG (Switzerland), Novo Nordisk (Denmark), Kedrion (Italy), Pfizer Inc. (US), Biogen (US) among others.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - - Global Forecast to 2021
The U.S. insomnia market is categorised into pharmacological treatments and non-pharmacological treatments. The U.S. insomnia pharmacological treatment market is projected to reach USD 4.24 Billion by 2021 from USD 3.38 Billion in 2016, growing at a CAGR of 4.6% from 2016 to 2021. The duration of insomnia can be from a day to years. Based on duration, insomnia is divided into three major categories, namely, transient insomnia (less than a month), short term insomnia (between 1 month and 6 months), and chronic insomnia (more than 6 months).
- Published: January 2017
- Price: $ 4950
- TOC Available:
-
Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogenic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, Wound care, Cardiovascular Diseases, Eye Disorders) & Region - Global Forecast to 2028
The global regenerative medicine market, valued at US$13.5 billion in 2022, stood at US$16.0 billion in 2023 and is projected to advance at a resilient CAGR of 25.1% from 2023 to 2028, culminating in a forecasted valuation of US$49.0 billion by the end of the period. The growth of this market is characterized by the increasing collaborations and partnerships by major market players, and the emerging applications in new therapeutic areas. Rising focus on personalized medicine and increasing regulatory approvals in regenerative medicine are also predicted to drive the market.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028
The global recombinant proteins market, valued at US$2.1 billion in 2022, stood at US$2.2 billion in 2023 and is projected to advance at a resilient CAGR of 7.2% from 2023 to 2028, culminating in a forecasted valuation of US$3.2 billion by the end of the period. Growth in the market can be attributed to factors such as rising incidence of chronic diseases, growing demand for biologics and biosimilars due to expiration of patents, rising demand for customized medicine and increasing government initiatives for R&D in life sciences research.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
US Patient Engagement Solutions Market by Therapy [Chronic (CVD, Diabetes), Women’s Health], Application (Home & Financial Health), Functionality (Telehealth, E-Prescribing, Scheduling, Billing), End User (Hospital, ASC, Payer, Patient) - Forecast to 2030
The US Patient Engagement Solutions market, valued at USD 12.86 billion in 2024, stood at USD 14.55 billion in 2025 and is projected to advance at a resilient CAGR of 11.4% from 2025 to 2030, culminating in a forecasted valuation of USD 25.01 billion by the end of the period. This growth is driven by increased adoption of digital health technologies, a shift toward value-based models and patient-centered care, the prevalence of chronic diseases, and greater use of smartphones, patient portals, and telehealth solutions.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Digital Therapeutics Market / DTx Market by Offerings (Platform, Virtual Reality/Games), Revenue Model (Subscription, Value Based), Application (Therapy (Diabetes, Obesity, CNS, Respiratory, CVD), Drug Adherence, Rehab/Patient care) - Global Forecast to 2028
The global digital therapeutics market, valued at US$4.4 billion in 2022, stood at US$6.1 billion in 2023 and is projected to advance at a resilient CAGR of 29.1% from 2023 to 2028, culminating in a forecasted valuation of US$21.9 billion by the end of the period. The rapid adoption of digital therapeutics is driven by the rising incidence of chronic diseases, surging investments from venture capital firms, and strategic partnerships between tech companies and healthcare providers.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), & End User - Global Forecast to 2028
The global continuous bioprocessing market, valued at US$201 million in 2022, stood at US$218 million in 2023 and is projected to advance at a resilient CAGR of 22.4% from 2023 to 2028, culminating in a forecasted valuation of US$599 million by the end of the period. The growth of the market is largely driven by rising demand for biopharmaceuticals, advantages of continuous bioprocessing over batch/fed-batch mode, and emergence of integrated end-to-end continuous bioprocessing.
- Published: November 2023
- Price: $ 4950
- TOC Available:
-
Oxygen Therapy Equipment Market by Product (Oxygen Source (Concentrator, Cylinder), Delivery Devices), Portability (Stationary, Portable), Application (COPD, Asthma, Cystic Fibrosis, Pneumonia), End User (Hospital, Home Care) - Global Forecast to 2022
The oxygen therapy equipment market is expected to reach USD 4.01 Billion by 2022 from USD 2.65 Billion in 2017, at a CAGR of 8.7% from 2017 to 2022. Factors driving the growth of this market are the increasing prevalence of respiratory disorders, rapid growth in the geriatric population, prevalence of tobacco smoking, preference towards home-based oxygen therapy, and technological advancements to develop novel products delivering oxygen therapy.
- Published: May 2017
- Price: $ 4950
- TOC Available:
-
Asia Pacific Patient Engagement Solutions Market by Therapy (Chronic [Obesity, Diabetes], Women’s Health), Functionality (Telehealth, E-Prescribing, Scheduling, Billing), End User (Hospital, ASC, Payer, Patient), Unmet Need, Investment - Forecast to 2030
The Asia Pacific Patient Engagement Solutions market, valued at USD 3.45 billion in 2024, stood at USD 3.97 billion in 2025 and is projected to advance at a resilient CAGR of 13.5% from 2025 to 2030, culminating in a forecasted valuation of USD 7.48 billion by the end of the period. This growth is driven by the rising demand for patient-centered and personalized care, a rapid expansion of telehealth and remote care frameworks, and more investments in digital healthcare infrastructure within the Asia Pacific region.
- Published: June 2026
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
